Investigating the molecular drivers of high-level clinical responses to bimekizumab in psoriatic disease
Introducing the BE UNIQUE phase 3b study.
Gudjonsson JE, Merola JF, Warren RB, McInnes IB, Szilagyi B, Simon-Hinsberg C, Jones P, Rastrick J, Cleverly A, Cutcutache I, Krueger JG
Journal of Investigative DermatologyIn the feed 1 Sep 2026, published online 1 Sep 2026, issue 2026 Sep 01, added to PubMed 1 Sep 2026
Topics: Psoriasis
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42678333 · DOI 10.1016/j.jid.2026.07.020